Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mobithron Advance is a multi-ingredient nutraceutical supplement developed and marketed by Brego Life Sciences for the management of osteoarthritis, specifically targeting knee osteoarthritis. The formulation contains three primary active components: undenatured type II collagen (Collavant n2), hyaluronic acid (Mobilee), and a patented Boswellia serrata gum extract (Apresflex). Undenatured type II collagen works via an oral tolerance mechanism to modulate the immune response and preserve joint cartilage. Hyaluronic acid provides essential lubrication and cushioning within the synovial fluid to improve joint mobility. Boswellia serrata extract acts as a potent anti-inflammatory agent by inhibiting the 5-lipoxygenase (5-LOX) enzyme, thereby reducing the production of pro-inflammatory leukotrienes. Universiti Sains Malaysia is currently conducting a prospective clinical trial to evaluate the long-term safety, efficacy, and cartilage-preserving effects of Mobithron Advance in patients with Kellgren-Lawrence grade 1 to 3 knee osteoarthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mobithron Advance.